Effect of Eszopiclone on Adherence to CPAP and Severity of Insomnia in Patients With COMISA
Status:
RECRUITING
Trial end date:
2025-12-20
Target enrollment:
Participant gender:
Summary
The comorbidity between obstructive sleep apnea (OSA) and insomnia (COMISA) is common, and associated with poorer sleep quality. CPAP adherence among COMISA patients is worst than among those with OSA only. The investigators will compare the effect of Eszopiclone 3mg or placebo for 14 days on adherence to CPAP after 30 days and after 6 months.